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Introduction
Human papillomavirus (HPV) is associated with 5% of all human cancers worldwide and around 30% of those cancers attributed to infectious agents [1] . The bivalent (Cervarix®) and quadrivalent (Gardasil®) prophylactic HPV vaccines comprise virus-like particles (VLP) based upon the major capsid protein (L1) of HPV16 and HPV18 [2] , which are the two genotypes associated with the majority (ca. 70%) of cervical cancers [3] . Gardasil® also contains VLP representing genotypes associated with the development of genital warts (HPV6 and HPV11). Both vaccines are highly efficacious at preventing persistent infection and cervical cancer precursors associated with HPV16 and HPV18 in vaccine trials [4] [5] [6] . These findings are starting to be reflected in post-licensure impact surveillance data following the implementation of national HPV immunization programmes [7] .
Neutralizing antibodies against HPV16 and HPV18 genotypes can be detected in the serum and genital secretions of vaccinees [8] , appearing to corroborate pre-clinical animal model data that support type-specific protection being mediated by neutralizing antibodies [9] [10] [11] .
A degree of cross-protection has also been demonstrated in vaccine trials against persistent infection and disease associated with some non-vaccine genotypes that are genetically related to the vaccine genotypes [4, 12] , a phenomenon that is also starting to be seen in vaccinated populations [7, 13] . The vaccines exhibit differential efficacy in this respect such that Cervarix® appears to be more protective against HPV31 (related to HPV16) than Gardasil® and this difference in efficacy is more marked for HPV45 (related to HPV18). These two non-vaccine genotypes alone are associated with ca. 10% of cervical cancers [3] . Cross-neutralizing antibodies can be detected in the serum and, in one study, the genital secretions of vaccinees [14] [15] [16] [17] [18] [19] [20] . These data are derived from relatively small immunogenicity studies, using one or both vaccines and carried out in different age groups, factors that may affect interpretation of whether the detection of such antibodies may be useful as a correlate or surrogate of vaccine-induced cross-protection. This report presents a systematic review and meta-analysis of available data on vaccine-induced neutralizing antibody seropositivity to non-vaccine incorporated HPV genotypes in order to provide a robust estimate of seroconversion rates against non-vaccine incorporated genotypes.
Methods
Search Strategy and Selection Criteria
A systematic search was undertaken of PubMed to identify papers reporting seropositivity data in conjunction with cross-neutralizing antibody titers against HPV non-vaccine genotypes. A combination of the following free terms were used to search titles and abstracts: ("HPV" or "Human Papillomavirus") and "Vaccine" and "Antibod*" and "Neutrali*". Two of the authors (SLB and AG) independently identified papers for analysis that were returned by the search terms up until June 2016. The a priori exclusion criteria were (i) description of a novel antigen, not a licensed HPV vaccine; (ii) description of antibodies elicited by natural infection, not vaccination; (iii) no neutralization data were presented; (iv) no cross-neutralization data were presented in the same or linked study specific paper; (v) not the primary evaluation of study neutralization data. Papers were initially excluded based upon title only, followed by a second round of exclusion based upon abstract content. Where the abstract stated or implied the inclusion of neutralization data within the published study the full text of the paper was reviewed.
Data Extraction
Key information retrieved for analysis included: participant characteristics (sex, age group), study characteristics (study setting, vaccine(s) used, sample collection times) and assay characteristics (assay format, target antigens, seropositivity, titers). The primary outcome measure was seropositivity to the two oncogenic vaccine incorporated genotypes (HPV16 and HPV18) and five non-vaccine incorporated genotypes (HPV31, HPV33, HPV45, HPV52 and HPV58) for which both efficacy and seropositivity have been consistently evaluated. The secondary outcome measure was the antibody titer to vaccine (HPV16, HPV18) and non-vaccine genotypes (HPV31, HPV45). Two of the authors (SBL and AG) performed the data extraction into a template spreadsheet and a data integrity check was performed (SB) before use.
Statistical methods
Estimates of seropositivity to each genotype following vaccination with either Gardasil® or Cervarix® were pooled using a DerSimonian-Laird random effects model, with logit transformed outcome variables. Cochran's Q-test was used as a test of interaction to see if the type of vaccine (or other variable) had a significant impact on seropositivity by genotype.
The association between vaccine efficacy (against persistent infection and CIN2+) as reported from clinical trials [12] and the mean seropositivity generated in this study was investigated. To propagate the uncertainty in these variables to the uncertainty in the linear relationship, we used a resampling technique known as the bootstrap [21] . To do this, we randomly sampled with replacement 1000 times from the set of positive and negative individuals in the populations of the studies used to estimate efficacy and seroprevalence. Each random sample was then used to construct a related estimate of vaccine efficacy, to construct a set of 1000 bootstrap estimates of vaccine efficacy. This was associated to 1000 similarly constructed estimates of seroprevalence using linear regression.
Vaccine efficacy and seropositivity were plotted on graphs. The uncertainty in the graphs represents the 95% range of predictions across the models. Exact 95% confidence intervals for data points were calculated using the Fisher's exact method for vaccine efficacy (1-odds ratio) and Clopper-Pearson for seroprevalence. Significance was taken at the 5% level and 95% confidence intervals used. Two-sided significance tests were used. R version 3.1.2 (R Development Core Team) was used for the analyses.
Results
We identified 304 articles of which 9 (representing 7 discrete studies) were included for this analysis (Figure 1 ) [14-20, 22, 23] . Details on the individual studies can be found in Table 1 . All studies included females (>95% of total assessed population) while one study [18, 23] also included males.
Three studies [14, 16, 19] included adolescent girls at the approximate target age for vaccination (11 -15 years old) while four studies [15, 17, 18, 20, 22, 23] included women over 18 years of age.
Two studies [16, 19] collected serum from adolescent girls taking part in national vaccination programmes, while five studies [14, 15, 17, 18, 20, 22, 23] collected serum from individuals in the context of a vaccination trial. Post-vaccination seropositivity was assessed at month 7 (1 month post third vaccine dose; M7) [14, 17, 18, 20, 22, 23] , month 12 (6 months post third vaccine dose; M12) [14-16, 18, 20, 23] , or in one study [19] , using data collected between month 7 and month 12. All studies [14-20, 22, 23] evaluated Cervarix® vaccinees while five studies [14, 17-20, 22, 23] also included Gardasil® vaccinees. All studies [14-20, 22, 23] used HPV pseudovirus targets HPV16, HPV18, HPV31 and HPV45 in neutralizing antibody tests with five studies [14-16, 18, 20, 23] including one or more additional Alpha-7 (related to HPV18) and Alpha-9 (related to HPV16) genotypes.
Seropositivity against HPV16 and HPV18 was essentially 100% following three doses of either Cervarix® or Gardasil® vaccine; a slightly lower (98%) HPV18 seropositivity was reported by one study following Gardasil® vaccination (data not shown). A higher proportion of Cervarix® vaccinees (86%; 95%CI 78 -91%; pooled estimate using the random effects model) were seropositive against HPV31 than Gardasil® vaccinees (61%; 39 -79%; p=0.011) (Figure 2) . Cervarix® vaccinees (50%; 37 -64%) also exhibited a markedly higher proportion of seropositivity against HPV45 than Gardasil® vaccinees (16%; 6 -36%; p=0.007). Pooled estimates for seropositivity against HPV33, HPV52 and HPV58 demonstrated no significant difference between the vaccines.
One of these studies [18, 23] examined bivalent and quadrivalent vaccine immunogenicity in a cohort of human immunodeficiency virus (HIV-1) infected individuals. Pooled estimates for seropositivity against HPV31 (Cervarix®: 87%; 95%CI 78 -92%; Gardasil®: 63%; 38 -83%; p=0.027) and HPV45 (Cervarix®: 47%; 33 -62%; Gardasil®: 11%; 4 -28%; p=0.002) not including these individuals were similar to the overall estimates.
There was a significant positive association between the overall seropositivity rates against nonvaccine incorporated genotypes and the vaccine efficacy data [12] These immunogenicity studies were carried out in adolescent girls (<18 years old) and adults (18 years or older) and included samples collected between one (M7) and six (M12) months after the third dose of vaccine. There were too few studies to allow a subset analysis, whereby the influence of vaccine, age group, and sampling time on genotype-specific seropositivity could be evaluated independently. Instead, seropositivity to HPV31 or HPV45 was evaluated using age group (irrespective of vaccine and sampling time) and sampling time (irrespective of vaccine and age group) as composite variables (Supplementary figure) . This was a similar approach to that taken for the evaluation of seropositivity stratified by vaccine, irrespective of age group and sampling time (Figure 2) . The pooled estimate for seropositivity against HPV31 in the adolescent age group (87%; 71 -95%) was slightly higher than that achieved in adults (66%; 50 -80%; p=0.045). Seropositivity against HPV45 for adolescents (31%; 15 -52%) was similar to that in adults (38%; 19 -61%; p=0.613). Overall, seropositivity against HPV31 (M7: 76%; 57 -89% vs. M12: 81%; 65 -91%; p=0.636) and HPV45 (M7: 35%; 19 -56% vs. M12: 51%; 33 -69%; 0.268) was similar regardless of sampling time.
The magnitude of the vaccine antibody responses were reported as the median or geometric mean titers for both vaccine (HPV16 and HPV18) and non-vaccine (HPV31 and HPV45) genotypes.
Although the magnitude of the titers for both vaccine and non-vaccine genotypes varied widely between studies, the non-vaccine genotype titers appeared to track their respective vaccine-type titers with some consistency (Figure 4) . HPV16 titers were a median 170 (inter-quartile range, IQR, 134 -262) fold higher than HPV31 titers for Cervarix® and a median 337 (201 -365) fold for Gardasil®. HPV18 titers were a median 478 (296 -1,413) fold higher than HPV45 titers for Cervarix® and a median 146 (108 -1,377) fold for Gardasil®.
Discussion
We performed a systematic review and meta-analysis of available seropositivity data against nonvaccine genotypes representing seven studies and approximately seven hundred individuals vaccinated with three doses of either Cervarix® or Gardasil® HPV vaccine [14-20, 22, 23] .
The estimated seroconversion rate for neutralizing antibodies against HPV31 was higher than that for HPV45, with Cervarix® vaccinees exhibiting higher rates of seroconversion against both of these genotypes than Gardasil® vaccinees. For HPV33, HPV52 and HPV58 the seroconversion rates were similar between the vaccines. There was a strong association between the seropositivity rates for these non-vaccine genotypes and the efficacy data reported from HPV vaccine trials [24, 25] .
HPV31 seropositivity has been shown to be coincident with a reduced risk of HPV31 acquisition post-vaccination with Cervarix®, although data supporting a similar relationship for HPV45 and HPV58 were lacking [26] .
This review incorporated data from adolescent girls around the target age for vaccination in national immunization programmes and from older women and included data collected between one and six months after the third vaccine dose. Of these variables, only the younger age at vaccination was shown to be associated with a higher seropositivity against HPV31. Where individual studies have compared the immune response to HPV vaccines in populations of similar ages, and using samples collected at the same time point post-vaccination, they have consistently demonstrated higher rates of seroconversion and/or higher titers against both HPV16 and HPV18 [14, 20, 22, 23] and nonvaccine genotypes [14, 17, 18, 20] following Cervarix® vaccination. Similarly, where studies compared serological responses between one and six months following the third vaccine dose, a small decline in seropositivity and/or titers was seen for both adolescents [14] and older women [17, 18, 20, 22, 23] . The issue of age is more problematic. Only one study in this review examined agedependent immune responses against vaccine and non-vaccine genotypes by stratifying a cohort of 18 -45 year old mid adult women into three sub-groups (18 -26, 27 -35 and 36 -45 years) and demonstrated some degree of age-related influence on responses against vaccine genotypes [22] , but the influence on responses against non-vaccine genotypes was less clear [17] . A stronger serological response elicited in adolescents compared to adult women has been demonstrated for both vaccines [27] [28] [29] [30] , but only against vaccine-incorporated genotypes using binding assays. The removal of data from one study [18, 23] comprising HIV-infected subjects made little difference to the pooled estimates for seropositivity against HPV31 and HPV45 suggesting, based on these limited study data, that the HIV serostatus of vaccine recipients may have little impact on HPV vaccine immunogenicity [31] .
The magnitude of the neutralizing antibody response varied between studies with responses against non-vaccine genotypes at least two orders of magnitude lower than those elicited against vaccineincorporated genotypes. The long-term durability of cross-neutralizing antibodies is unclear; thus far, antibodies against HPV31 and HPV45 have been detected out to twenty-four months postvaccination [17, 22] . In the same vaccine comparison study, responses against HPV16 and HPV18 remain robust out to 5 years [32] .
There are several shortcomings to this study. The small number of available studies limited a robust evaluation for some non-vaccine genotypes, notably HPV33, HPV52 and HPV58. This is particularly true for estimating seroconversion rates for Gardasil® vaccinees, which were represented by a single study or pair of studies in some cases. The small number of available studies also precluded an analysis of the influence of each variable (vaccine, age group, sampling time) independently.
Thus, the differences in seropositivity due to the vaccine may have been confounded by the influence of the age at vaccination and the sampling time post third dose. This confounding likely led to the high heterogeneity scores seen here and potentially obscured more subtle effects of age and sampling time on seropositivity.
This review evaluated studies incorporating a three-dose schedule. Reduced dose arms in vaccine trials have demonstrated non-inferior seropositivity to vaccine genotypes and similar vaccine efficacy [33, 34] , resulting in a recommendation for a two dose schedule to be adopted worldwide [35] . However, reduced seropositivity to HPV31 has been demonstrated for less than three doses [36] , which is likely to be a factor in the reduced vaccine efficacy observed against non-vaccine genotypes HPV31 and HPV45 in a post-hoc analysis of Cervarix® trial data [37] . Nevertheless, this report represents an analysis of the only available functional data with which to evaluate seroconversion rates against non-vaccine incorporated genotypes.
Recently, the nonavalent Gardasil®9 vaccine comprising additional genetically related genotypes HPV31, HPV33, HPV45, HPV52 and HPV58 has demonstrated efficacy in a three dose schedule [38] and non-inferiority of antibody responses for two doses [39] . A nonavalent vaccine has the potential to reduce the incidence of cervical cancer by over 90% [3, 40] , is expected to be cost effective [41, 42] . Nonavalent vaccine efficacy against persistent infection or low grade disease associated with any of these additional genotypes in the per protocol population was ≥96% which is considerably higher than any beneficial cross-protective vaccine efficacy induced by either the bivalent or quadrivalent vaccines against these genotypes [24, 25, 43] . Although national immunization programmes will likely adopt the nonavalent vaccine in time, to date tens of millions of adolescent girls have been vaccinated with the bivalent or quadrivalent vaccine [44] , for which a better understanding of their immunogenic properties including the seroconversion rates, breadth, magnitude and durability of the antibody responses against vaccine and non-vaccine genotypes is warranted. 
Contributions
. Pooled estimates for seroconversion against non-vaccine incorporated genotypes
Estimates of seropositivity to each genotype following vaccination with either Gardasil® or Cervarix® pooled using a DerSimonian-Laird random effects model, with logit transformed outcome variables. Test for subgroup differences using Cochran's Q-test. confidence intervals for the neutralization seropositivity data. The best fitting linear relationship between the two variables (black line) and the 95% range of bootstrap estimates for this relationship (dotted lines) is also shown. Exact 95% confidence intervals for data points were calculated using the Fisher's exact method for vaccine efficacy (1-odds ratio) and Clopper-Pearson for seropositivity. 
